Physician profile
James T Wang
NPI 1013091396
$37,793.80
in general payments reported to CMS, 2019-2025
44 companies · $7,835 in 2025
The $7,835 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,477 · 2020: $2,791 · 2021: $4,411 · 2022: $6,956 · 2023: $5,427 · 2024: $5,898 · 2025: $7,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,806.44 |
| Education | $353.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,238.13 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Incyte Corporation | $4,348.87 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $2,955.70 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $2,421.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,386.37 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $2,359.99 | 2019-2025 | Ilumya, Blu-U, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,484.61 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Genzyme Corporation | $1,429.89 | 2019-2025 | |
| Ucb, INC. | $1,387.79 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,197.42 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $1,143.51 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Lilly USA, LLC | $1,114.55 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $1,093.74 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $969.09 | 2019-2025 | Emrosi |
| Regeneron Healthcare Solutions, INC. | $782.58 | 2020-2025 | Dupixent, Libtayo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $778.58 | 2019-2025 | Otezla, Otezla |
| Epi Health, LLC | $777.62 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $761.08 | 2019-2022 | |
| Dermavant Sciences, INC. | $729.51 | 2022-2024 | Vtama |
| Leo Pharma INC. | $549.36 | 2020-2025 | Adbry |
| Almirall LLC | $437.42 | 2019-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $381.46 | 2019-2025 | |
| Revance Therapeutics, INC. | $234.62 | 2024-2025 | Daxxify, Daxi |
| Intuitive Surgical, INC. | $234.46 | 2020 | |
| Organogenesis INC. | $213.90 | 2020-2023 | Puraply |
| Botanix Sb INC | $208.94 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $198.94 | 2020-2021 | |
| Dermira, INC. | $180.91 | 2019-2021 | |
| Allergan, INC. | $142.23 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $126.73 | 2025 | Clear+Brilliant |
| Vyne Pharmaceuticals INC. | $67.90 | 2020-2021 | |
| Strata Skin Sciences, INC. | $62.98 | 2022-2025 | Xtrac |
| Prugen, INC. Pharmaceuticals | $54.92 | 2019-2020 | |
| Mimedx Group, INC. | $53.23 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.52 | 2022-2023 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Organon LLC | $34.73 | 2025 | Vtama |
| Promius Pharma LLC | $34.67 | 2019 | |
| Nabriva Therapeutics, Plc | $25.09 | 2020 | |
| Celgene Corporation | $23.25 | 2019 | |
| Sebela Pharmaceuticals INC. | $22.36 | 2022 | |
| Biofrontera INC. | $21.88 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $13.11 | 2024 | Ycanth |
| Sandoz INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.